# A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

> **NCT01232556** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 338 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Inotuzumab ozogamicin
- **DRUG:** Rituximab
- **DRUG:** rituximab + gemcitabine
- **DRUG:** rituximab +bendamustine

## Key facts

- **NCT ID:** NCT01232556
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-04
- **Primary completion:** 2014-03-28
- **Final completion:** 2014-03-28
- **Target enrollment:** 338 (ACTUAL)
- **Why stopped:** The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety issues were identified.
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232556, "A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01232556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*